title: [Influence of co-stimulatory molecules B7-H4 expression on the prognosis of patients with gastric cancer treated with cytokine-induced killer cells adoptive immunotherapy].
abstract: OBJECTIVE
  To investigate the influence of co-stimulatory molecules B7-H4 expression on prognosis of gastric cancer patients treated by cytokine-induced killer cells (CIK cells) adoptive immunotherapy.
  
  
  METHODS
  Clinical data of 156 cases of gastric cancer patients were retrospectively analyzed. Patients were divided into chemotherapy group(n=81) and chemotherapy combined with CIK cell therapy group(n=75). B7-H4 expression was detected in the surgical specimens of gastric cancer patients by immunohistochemistry assay. Disease-free survival was compared between the chemotherapy group and the CIK group at different expression levels of B7-H4.
  
  
  RESULTS
  The difference was not statistically significant in all clinical and pathological data between the chemotherapy group and the CIK treatment group (P>0.05). The postoperative median tumor-free survival in two groups was 18.0 and 45.0 months, respectively, and the difference was statistically significant (chi(2)=11.631, P=0.001). The postoperative median survival time was 27.0 and 49.0 months, respectively, and the difference was statistically significant (chi(2)=10.907, P=0.001). In 86 patients with low B7-H4 expression, the median tumor-free survival time was 32.0 and 62.0 months, respectively, and the difference was statistically significant (chi(2)=4.663,P=0.03). In 70 patients with high B7-H4 expression, the median tumor-free survival time was 11.0 and 18.0 months, respectively, and the difference was statistically significant (chi(2)=11.971, P=0.001).
  
  
  CONCLUSIONS
  The median tumor-free survival time of patients with gastric cancer may be further improved by chemotherapy combined with CIK cell therapy, regardless of the level of B7-H4 expression.
authors.affiliation: Institute of Biotechnology, Key Laboratory of Clinical Immunology of Jiangsu Province, Soochow University, Suzhou 215123, China.
authors.forename: Jing-ting
authors.initials: JT
authors.lastname: Jiang
authors.forename: Chang-ping
authors.initials: CP
authors.lastname: Wu
authors.forename: Yue-ping
authors.initials: YP
authors.lastname: Shen
authors.forename: Lu
authors.initials: L
authors.lastname: Zheng
authors.forename: Jun
authors.initials: J
authors.lastname: Wu
authors.forename: Mei
authors.initials: M
authors.lastname: Ji
authors.forename: Bin
authors.initials: B
authors.lastname: Xu
authors.forename: Lu-jun
authors.initials: LJ
authors.lastname: Chen
authors.forename: Yu-gang
authors.initials: YG
authors.lastname: Wu
authors.forename: Xiao
authors.initials: X
authors.lastname: Zheng
authors.forename: Yi-bei
authors.initials: YB
authors.lastname: Zhu
authors.forename: Bin-feng
authors.initials: BF
authors.lastname: Lu
authors.forename: Xue-guang
authors.initials: XG
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018122:B7-1 Antigen / Q000378:metabolism*; D055612:Cytokine-Induced Killer Cells; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000175:diagnosis* / Q000378:metabolism* / Q000628:therapy; D060907:V-Set Domain-Containing T-Cell Activation Inhibitor 1
chemical_list: D018122:B7-1 Antigen; D060907:V-Set Domain-Containing T-Cell Activation Inhibitor 1; C475826:VTCN1 protein, human